Los resultados actualizados del estudio de Fase 2 CAPTIVATE demuestran el beneficio clínico sostenido de IMBRUVICA® (ibrutinib) en combinación con ventoclax como tratamiento de primera línea de duración finita en pacientes con leucemia linfocítica crónica, incluidos aquellos con enfermedad de alto riesgo
June 17, 2024 09:50 ET
|
Janssen Cilag International NV
Al cabo de 5 años, el 67 por ciento de los pacientes no presentaban progresión de la enfermedad, con una supervivencia global del 96 por ciento en todos los pacientes tratados 1 BEERSE, BÉLGICA,...
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024 09:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
Les résultats actualisés de l’étude CAPTIVATE la Phase 2 démontrent les avantages cliniques durables d’IMBRUVICA® (ibrutinib) à durée fixe associé au venetoclax dans un traitement de première intention pour les patients atteints de leucémie lymphoïde chronique, y compris ceux présentant une maladie à haut risque
June 17, 2024 09:33 ET
|
Janssen Cilag International NV
Au bout de 5 ans, 67 pour cent des patients ne présentaient aucune progression de la maladie et la survie globale était de 96 pour cent pour tous les patients traités 1 BEERSE, BELGIQUE, 17 juin...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
June 17, 2024 08:44 ET
|
Evaxion Biotech
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic...
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
June 17, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according...
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024 08:30 ET
|
Aprea Therapeutics
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet...
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
June 17, 2024 08:05 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
June 17, 2024 08:00 ET
|
Salarius Pharmaceuticals, Inc.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...